Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1696267

Cover Image

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1696267

Italy Probiotic Food Supplements Market - 2025-2032

PUBLISHED:
PAGES: 180 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 3175
PDF & Excel (Multiple User License)
USD 3500
PDF & Excel (Enterprise License)
USD 6850

Add to Cart

Italy probiotic food supplements market reached US$ 642.36 million in 2024 and is expected to reach US$ 959.84 million by 2032, growing with a CAGR of 5.15% during the forecast period 2025-2032.

The Italian probiotic food supplements market has been experiencing steady growth, driven by increasing consumer awareness of gut health and digestive wellness. According to the Italian Ministry of Health, the demand for probiotic supplements has shown a consistent upward trend, reflecting a shift toward preventive healthcare solutions.

The Italian National Institute of Statistics (ISTAT) also reports that a significant portion of Italian consumers regularly use probiotic products, with notable participation among individuals aged 35-60. This trend is further supported by the country's aging population, as probiotics play a crucial role in improving digestion and immune function, particularly for older adults.

Market Dynamics

Growing Demand for Personalized Nutrition

The increasing demand for personalized and DNA-based probiotic supplements is shaping the Italy probiotic food supplements market as consumers seek tailored health solutions. With advancements in microbiome research, individuals are becoming more aware of how gut health influences overall well-being. This has driven demand for probiotics customized to genetic profiles, dietary habits, and lifestyle factors.

According to data from the Italian Ministry of Health, over 68% of Italians in 2023 reported an interest in personalized nutrition solutions, highlighting a strong consumer shift toward targeted dietary interventions. This trend is further supported by the European Food Safety Authority (EFSA), which has observed a rise in applications for probiotic-related health claims, indicating growing scientific and commercial interest in the segment.

Stringent Regulatory Approvals and Compliance Requirements

Stringent regulatory approvals and compliance requirements are restraining the growth of the probiotic food supplements market in Italy, as companies must adhere to strict guidelines set by both national and European authorities. In 2023, the EFSA rejected over 60% of probiotic health claim applications from Italy due to insufficient proof of efficacy, according to the Italian Ministry of Health. This regulatory hurdle increases both time and costs for manufacturers, limiting the entry of innovative probiotic formulations into the market.

The Italian National Institute of Health (ISS) reported in 2024 that over 15 probiotic strains submitted for approval faced significant delays due to complex dossier requirements and extended review periods. These regulatory barriers have particularly affected small and mid-sized businesses, which struggle to meet the high costs and scientific documentation demands.

Segment Analysis

Italy probiotic food supplements market is segmented based on ingredient, dosage, application, and age.

Gastrointestinal Health Dominates Italy Probiotic Food Supplements Market Due to Rising Digestive Disorders, Consumer Preference for Natural Solutions

Gastrointestinal health holds a significant share in the Italy probiotic food supplement market due to rising consumer awareness of gut health benefits. Increasing digestive disorders, such as bloating and irritable bowel syndrome (IBS), drive demand for probiotics. Italians prioritize natural and functional foods, making probiotics a preferred choice for maintaining gut balance.

Global companies are responding to Italy's growing probiotic supplement market by launching innovative, science-backed formulations targeting gut health. In May 2021, Probi and Perrigo signed a semi-exclusive agreement to introduce premium probiotic products for digestive and immune health in Italy. This type of partnership strengthens global companies' presence in the Italy probiotic supplement market.

Unmet Needs

One significant unmet need is the demand for personalized probiotic solutions tailored to individual health profiles. While the market offers a variety of probiotic supplements, many are formulated for general use without considering specific factors such as age, gender, lifestyle, and existing health conditions. Personalized probiotics that address individual microbiome compositions and health goals could enhance efficacy and consumer satisfaction.

Another area requiring attention is the need for comprehensive consumer education regarding the appropriate use and benefits of probiotic supplements. Many consumers lack an understanding of the differences between various probiotic strains, their specific health benefits, and the importance of factors like dosage and duration of use. This knowledge gap can lead to suboptimal product choices and diminished health outcomes.

Competitive Landscape

The Italy probiotic food supplement market is highly competitive, driven by local and global players focusing on gut health solutions, with companies differentiating through innovative formulations like multi-strain probiotics, synbiotics, and clean-label products. The major players in the market include Chiesi Farmaceutici S.p.A, Zeta Pharmaceuticals Group, DuLac Farmaceutici, Deltha Pharma srl, IMO SpA, Citozeatec srl, Nestle Italiana SpA (Nestle Italiana SpA), BioGaia, Amway Italy s.r.l. (Amway), Now Foods.

Key Developments

  • In July 2024, BioGaia signed an exclusive distribution agreement with Recordati in Italy, replacing a previous sub-license. The long-term deal grants Recordati direct rights to distribute BioGaia's probiotic products under the Reuflor brand.

Why Choose DataM?

  • Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
  • Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
  • White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
  • Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
  • Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
  • Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies
Product Code: FB9431

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Ingredient
  • 3.2. Snippet by Dosage
  • 3.3. Snippet by Application
  • 3.4. Snippet by Age

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Demand for Personalized Nutrition
      • 4.1.1.2. Innovation in Probiotic Formulation
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent Regulatory Approvals and Compliance Requirements
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Sustainability Analysis
  • 5.6. Unmet Needs
  • 5.7. DMI Opinion

6. By Ingredient

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ingredient
    • 6.1.2. Market Attractiveness Index, By Ingredient
  • 6.2. Lactobacillus*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Streptococcus
  • 6.4. Bifidobacterium
  • 6.5. Others

7. By Dosage

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
    • 7.1.2. Market Attractiveness Index, By Dosage
  • 7.2. Tablet*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Capsules
  • 7.4. Liquid
  • 7.5. Powder
  • 7.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Gastrointestinal Health*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Gut Microbiota/Microbiome Balance
    • 8.2.4. Digestion
    • 8.2.5. Constipation
    • 8.2.6. Bloating
    • 8.2.7. Diarrhea
    • 8.2.8. Leaky Gut
    • 8.2.9. Inflammation
    • 8.2.10. Immune System
    • 8.2.11. Others
      • 8.2.11.1. Gluten sensitivity
      • 8.2.11.2. Abdominal Pain
      • 8.2.11.3. GERD/Helicobacter pylori
      • 8.2.11.4. Antibiotic-Associated Diarrhea/Post-Antibiotic Treatment
      • 8.2.11.5. Gut Flora/Gut Microbiome Restoration
      • 8.2.11.6. Others
  • 8.3. Vaginal Health
  • 8.4. Urinary Tract Health
    • 8.4.1. Kidney Stones
    • 8.4.2. UTIs
    • 8.4.3. Others
  • 8.5. Oral Health
  • 8.6. Anti/Healthy Ageing
  • 8.7. Allergies/Asthma
  • 8.8. Bone & Joint Health
    • 8.8.1. Osteoarthritis
    • 8.8.2. Osteoporosis/Low Mineral Bone Density
    • 8.8.3. Inflammation
  • 8.9. Brain/Mental Health
    • 8.9.1. Sleep
    • 8.9.2. Cognition
    • 8.9.3. Mood
    • 8.9.4. Depression
    • 8.9.5. Focus
  • 8.10. Cardiovascular Health
  • 8.11. Circulation
  • 8.12. Energy/Fatigue Reduction
  • 8.13. Metabolic Syndrome/Blood Glucose
  • 8.14. Liver Health
  • 8.15. Energy
  • 8.16. Immunity/Respiratory Infections
  • 8.17. Nutrient Absorption
  • 8.18. Skin-Hair-Nails
    • 8.18.1. Atopic Dermatitis & Eczema
    • 8.18.2. Acne
    • 8.18.3. Rosacea
    • 8.18.4. Hair Growth/Hair Loss
    • 8.18.5. Skin Microbiome
    • 8.18.6. Others
  • 8.19. Sports
  • 8.20. Women's Health
    • 8.20.1. Fertility
    • 8.20.2. Menopause
    • 8.20.3. Pregnancy
    • 8.20.4. Pcos
    • 8.20.5. Vaginal Health & Health Vaginal Microbiome
    • 8.20.6. Vaginal Infections (Bv/Vvc)
    • 8.20.7. Pregnancy Outcomes
    • 8.20.8. Others
  • 8.21. Men's Health & Men's Fertility
  • 8.22. Weight Management
  • 8.23. Pediatric Health
    • 8.23.1. Colic
    • 8.23.2. Constipation
    • 8.23.3. Regurgitation
    • 8.23.4. Atopic Dermatitis
    • 8.23.5. Others
  • 8.24. Others

9. By Age

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age
    • 9.1.2. Market Attractiveness Index, By Age
  • 9.2. Infant*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Children
  • 9.4. Adults
  • 9.5. Seniors

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Chiesi Farmaceutici S.p.A*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Zeta Pharmaceuticals Group
  • 11.3. DuLac Farmaceutici
  • 11.4. Deltha Pharma srl
  • 11.5. IMO SpA
  • 11.6. Citozeatec srl
  • 11.7. Nestle Italiana SpA
  • 11.8. BioGaia
  • 11.9. Amway Italy s.r.l. (Amway)
  • 11.10. Now Foods

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!